Novo Nordisk (NVO) shares are tumbling on Friday after the Danish pharmaceutical giant posted disappointing headline results from a late-stage cardiovascular clinical trial. In its press release, the company said its experimental anti-inflammatory drug, ziltivekimab, failed to hit its primary endpoint of reducing major adverse cardiovascular events in high-risk patients.
Following today’s decline, Novo Nordisk stock is down more than 10% year-to-date.
